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Megalin or low-density lipoprotein receptor-related protein-2 is a member of the low-density
lipoprotein receptor family, which has been linked to Alzheimer’s disease (AD) by clearing
brain amyloid β-peptide (Aβ) across the blood–cerebrospinal fluid barrier at the choroid
plexus. Here, we found a soluble form of megalin secreted from choroid plexus epithelial
cells. Soluble megalin levels were also localized in the human cerebrospinal fluid (CSF),
being reduced in AD patients. We have also shown that soluble megalin binding to Aβ is
decreased in the CSF of AD patients, suggesting that decreased sequestration of Aβ in the
CSF could be associated with defective clearance of Aβ and an increase of brain Aβ levels.
Thus, therapies, which increase megalin expression, at the choroid plexus and/or enhance
circulating soluble megalin hold potential to control brain Aβ-related pathologies in AD.
Keywords: megalin, Alzheimer’s disease, cerebrospinal fluid, choroid plexus, epithelial cells, amyloid β, clearance,
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INTRODUCTION
Megalin, a transmembrane glycoprotein and member of the low-
density lipoprotein (LDL) receptor-related family, is an endocytic
receptor expressed on the apical surface of several epithelial cells
that internalizes a variety of ligands including nutrients, hormones
and their carrier proteins, signaling molecules, morphogens, and
extracellular matrix proteins. In adults, megalin expression is
restricted to the central nervous system (CNS), the choroid plexus
(Chun et al., 1999; Carro et al., 2005), the ependymal cells of the lat-
eral ventricles (Gajera et al., 2010), and to the spinal cord (Wicher
et al., 2006). Megalin has a relatively large extracellular domain,
responsible for ligand binding, a small cytoplasmic domain, and
a single transmembrane domain (Marzolo et al., 2003). Based on
the important roles of its ligands and its tissue expression pat-
tern, megalin has been recognized as an important component
of many pathological conditions, including Alzheimer’s disease
(AD). Megalin is required for efficient brain Aβ clearance, mediat-
ing the transport of Aβ from the cerebrospinal fluid (CSF) into
the choroid plexus epithelium (Hammad et al., 1997; Alvira-
Botero and Carro, 2010; Pascale et al., 2011). Megalin is also
expressed in neurons, where it interacts with APP and FE65, par-
ticipating in the neurite branching. In AD, this interaction has
been demonstrated to be important in Aβ-mediated neurotoxicity
(Alvira-Botero et al., 2010).
Another member of LDL receptor-related family, the low-
density lipoprotein receptor-related protein 1 (LRP-1), has been
mainly implicated in blood–brain barrier (BBB) Aβ clearance (Bell
et al., 2007), but it has also been reported to be expressed in the
choroid plexus (Kounnas et al., 1994), where it is involved in the
clearance of Aβ in the CSF. LRP-1 is a substrate for both β-secretase
(BACE) and γ-secretase (Von Arnim et al., 2005). BACE cleaves the
N-terminus extracellular domain of LRP-1, which releases soluble
LRP-1 (Von Arnim et al., 2005), implying circulation of Aβ regula-
tion, and possibly Aβ-related brain pathology (Sagare et al., 2007).
Megalin has also been demonstrated to be released into the
extracellular medium (Bachinsky et al., 1993; Spuch et al., 2010).
These soluble forms are fragments of approximately 200–220 kDa,
suggesting that they are truncated forms of the membrane-bound
megalin. Indeed, the transmembrane domain of megalin is also a
substrate for the γ-secretase complex (Zou et al., 2004; Biemesder-
fer, 2006). Megalin has also been found in urine-derived exosomes
(Pisitkun et al., 2004). It is therefore possible that under some
pathophysiological conditions, the levels of megalin associated
with exosomes or megalin derived from protease-mediated shed-
ding of the extracellular domain could be affected and could serve
as a diagnostic biomarker. In addition, the secretion of soluble
forms of megalin could be a physiological mechanism to regu-
late the availability of ligands and/or to transport ligands. Thus,
the secretion of soluble fragments of megalin into the CSF could
signify a relevant mechanism controlling the availability of the
receptor, storage of the ligands in the CSF, and its function at the
blood–CSF barrier.
Taking these data together, we hypothesize that megalin could
also be proteolytically processed by the choroid plexus epithelial
cells, which would lead to the release of a secreted form of mega-
lin into the medium. In this study, we find that a soluble form
of megalin exists in the CSF, and its levels are decreased in AD
patients, compromising brain Aβ clearance.
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MATERIALS AND METHODS
HUMAN SAMPLE
We included three groups of subjects: (1) AD patients; (2) Parkin-
son’s disease (PD) patients; and (3) elderly non-demented con-
trols. For AD patients, the diagnosis was established according
to the National Institute on Neurological Disorders and Stroke,
and the Alzheimer’s Disease and Related Disorders Association
(NINDS–ADRDA) guidelines (McKhann et al., 2011). Parkinson’s
patients were diagnosed according to the criteria of probability
(Gelb et al., 1999). Disease severity was evaluated using mini-
mental state examination (MMSE) scores (Table 1). Inclusion cri-
teria for cognitively normal older individual subjects were MMSE
scores of 24–30, with no history or clinical signs of neurological
or psychiatric disease or cognitive symptoms. Approval for sample
ascertainment and collection was obtained from the Ethics Com-
mittee of the Hospital “12 de Octubre.” Written informed consent
was obtained from all participants or representatives prior to their
participation.
A total of 85 CSF samples were included in this study from
patients with AD, PD, as well as healthy control subjects obtained
at the Hospital 12 de Octubre (Table 1). CSF collection was con-
ducted following standard operating procedures. Briefly, 12 ml of
CSF were collected in a polypropylene tube by lumbar puncture in
the L3–L4 or L4–L5 interspaces and centrifuged at 2000× g at 4°C
for 10 min. The supernatant was aspirated, gently mixed to avoid
possible gradient effects, and aliquoted into polypropylene tubes
that were stored at−80°C for subsequent biochemical analyses.
Choroid plexus tissue was obtained from the Department of
Pathology and Neuropathology (Xerencia de Xestión Integrada de
Vigo-SERGAS), following the Spanish legislation guidelines. The
samples analyzed for AD studies included choroid plexus from
stages V–VI (n= 9, 76.4± 4.1 years), and age-matched controls
(n= 6, 69.6± 3.1 years).
CELL CULTURE
Choroid plexus epithelial cell cultures were prepared as described
previously (Carro et al., 2002). Choroid plexus were dissected
from 3- to 5-day-old Wistar rats (Charles River). Choroid plexus
epithelial cells were seeded on laminin-coated 24-well plates with
Dulbecco’s modified Eagle’s medium (Lonza) containing 10% fetal
bovine serum (Lonza), 2 mM glutamine (Sigma), 100 U/ml peni-
cillin (Lonza), and 100µg/ml streptomycin (Lonza). Cells were
grown to confluence for 5–7 days at 37°C in a humidified atmos-
phere containing 5% CO2, and serum starved for 2 h. Then, human
oligomeric Aβ40 (5µg/ml; AnaSpec, Inc., San Jose, CA, USA) was
added. Aβ40 was previously dissolved in acetic acid 0.1M, and then
dissolved in sterile distilled water as reported by Dietrich et al.
(2008). At different times after stimulation, cell culture medium
was collected, and cells were either fixed for immunocytochemical
processing or homogenized for immunoblot determination.
MEASUREMENT OF EXTRACELLULAR/SOLUBLE MEGALIN
Culture medium was replaced with fresh medium about 2 h prior
to Aβ treatment. Cells were stimulated with 5µg/ml of Aβ40 at
37°C for 24 and 48 h. Then, culture medium was collected and
centrifuged at 2000× g for 3 min to pellet any possible suspended
cells or debris in the medium. The supernatant medium was
Table 1 | Demographic characteristics of patients with








Average age 76.1±1.4 67.7±1.6 67.5±1.9 NA
Gender (M/F) 14/15 19/13 14/10 NA
Mean MMSE 19.4±0.8* 28.0±0.5 30.0±1.5 p<0.05*
Mean onset 2.5±0.2 4.1±0.8 nd NA
CSF Aβ42 (pg/ml) 422.8±58.2* nd 768.3±163.9 p<0.05*
CSF Tau (pg/ml) 664.8±7.9** nd 379.1±47.3 p<0.001**
MMSE, mini-mental state examination; CSF, cerebrospinal fluid; AD, Alzheimer’s
disease; PD, Parkinson’s disease; NA, not applicable; nd, not determined.
Results are expressed as mean±SEM.
*p<0.05.
**p<0.001 versus control subjects.
collected, and stored at −80°C for immunoblot analysis or mass
spectrometry.
IMMUNOBLOTTING AND IMMUNOPRECIPITATION
Cell lysates and medium from choroid plexus epithelial cultures
and SCF samples were analyzed by immunoblot. Protein content
was determined by the DC method (Bio Rad Laboratories, Inc.).
Equal amounts of protein (50µg/lane) were boiled and separated
by SDS-PAGE (5–20%), and transferred onto PVDF membranes
(Millipore). Non-specific binding was blocked by incubation in
5% non-fat milk in Tris-buffered saline (100 mM NaCl, 10 mM
Tris, pH 7.4) containing 0.2% Tween (TTBS) for 1 h at room tem-
perature. Afterwards, membranes were incubated overnight at 4°C
with different antibodies in TTBS with 3% bovine serum albu-
min. We used one specific homemade antibody that recognizes
the specifically soluble megalin described by Ishida et al. (2006).
The antibody anti-megalin (mAb2E12) recognizes a soluble 210-
kDa molecule lacking a cytoplasmic domain, which corresponds
with a truncated form of membrane-bound megalin. For the trun-
cated form of LRP1 (85 kDa), we used the anti-LRP1 antibody
(EPR3724, Abcam) corresponding to aa 4450 to the C-terminus of
LRP1 and truncated form of LRP1. Protein loading was monitored
using a mouse monoclonal antibody against β-actin (1:10000,
Sigma-Aldrich, MO, USA).
The interaction of Aβ with megalin and LRP-1 was assessed by
co-immunoprecipitation. In these experiments, megalin or LRP-1
was immunoprecipitated from CSF by incubating 500µl of CSF
sample with either anti-megalin (1:100, Santa Cruz) or anti-LRP
(1:200,Abcam) antibodies, on a rotating wheel overnight, followed
by the addition of protein A-agarose and an additional incubation
for 2 h. The immunocomplex was subsequently washed twice with
washing buffer (20 mM Tris, pH 7.4, 150 mM NaCl). Thirty micro-
liters of volume samples including loading buffer were boiled
for 5 min. Then, they were resolved on SDS-polyacrylamide gel,
and transferred onto a PVDF membrane. Following incubation
with phosphate buffer (PB 0.1M supplemented with 0.1% Tween-
20, containing 5% low fat milk to block non-specific binding
sites), membranes were incubated with anti-Aβ antibody (1:500,
MBL, Nagoya, Japan) at 4°C overnight, and then with a secondary
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antibody conjugated with horseradish peroxidase (Bio-Rad). The
immunoreactive signal was revealed in a chemiluminiscent sub-
strate detection system ECL (Bio-Rad). Protein band densities
were quantified using ImageJ software (NIH, Bethesda, MD, USA)
after scanning the images with ImageQuant software (GE Health-
care). To verify the protein–protein interaction, Aβ was immuno-
precipitated by incubating with anti-Aβ antibody (1:500, MBL,
Nagoya, Japan), and the co-immunoprecipitated proteins were
identified on a Western blot with anti-megalin (1:5000, Abcam),
and anti-LRP (1:20000, Abcam). In addition, the amount of pro-
teins immunoprecipitated by their own primary antibodies was
routinely measured on Western blots.
MASS SPECTROMETRY
Culture medium samples from choroid plexus epithelial cell cul-
ture were loaded on a SDS-PAGE 4–20% gel. A protein band
matching the molecular weight of megalin was excised from the gel
and destained. In-gel digestion was carried out sequentially with
trypsin and endopeptidase Asp-N for 16 h each. To validate the
presence of soluble megalin in culture medium, this protein was
identified by a MALDI-TOF/TOF mass spectrometer 4800 Pro-
teomics Analyzer (Applied Biosystems, Framingham, MA, USA)
and 4000 Series Explorer™ software (Applied Biosystems).
IMMUNOCYTOCHEMISTRY
The non-treated and Aβ40-treated choroid plexus epithelial cells
were fixed with 4% formaldehyde in PB (pH 7.4) at room tem-
perature for 30 min. Cells were then stained with anti-megalin
(mAb2E12, 1:500, gift from Tetsuya Ishida, Kagawa University
School of Medicine, Japan) antibody at 4°C, overnight.
After the cells were washed three times with PB, secondary
donkey anti-mouse IgG 488 (1:1000, FluoProbes®, Interchim)
was added to the cells and incubated at room temperature for
1 h in the dark. The cells were then washed three times, sealed
with VECTASHIELD (Vector Laboratories) and observed under
a Zeiss LSM 510 Meta scanning laser confocal microscope (Leica
Microsystems).
Levels of endogenous Aβ42, and tau in CSF samples were deter-
mined using the Aβ42 human ELISA Innotest kit (Innogenetics),
and Tau human ELISA Innotest kit (Innogenetics), respectively.
STATISTICAL ANALYSIS
The Kolmogorov–Smirnov Z test was used to analyze the distri-
bution of the samples. For normally distributed data, statistical
significance was tested using Student’s t -test when comparing
two groups, and a two-way ANOVA followed by post hoc Mann–
Whitney test was used for multiple comparisons. All calculations
were made using SPSS v15.0 software. Statistical significance was
set at p< 0.05.
RESULTS
Aβ40-INDUCED DECREASE IN EXTRACELLULAR MEGALIN
Megalin is known to be secreted into the extracellular matrix
as a soluble form, although the mechanism(s) and molecular
pathways(s) underlying its secretion have not been identified.
Figure 1A shows the immunocytochemistry results, in which
choroid plexus epithelial cells were stained with soluble mega-
lin antibody. Under non-stimulated conditions, soluble megalin
was detected in the extracellular space. We further investigated the
possibility that Aβ could alter the levels of megalin in the culture
medium. As shown in Figure 1B, the immunoblotting of soluble
megalin showed a band (at approximately 210 kDa), correspond-
ing with the extracellular form of megalin (Ishida et al., 2006). To
substantiate this, the band corresponding to soluble megalin was
excised and analyzed by mass spectrometry after an in-gel diges-
tion. The soluble megalin band was further confirmed, with amino
acid coverage of 34%.
Because megalin has a greater affinity for Aβ40 than for Aβ42
(Deane et al., 2004), we used the former, more soluble form
of Aβ40 in this study. Soluble megalin levels were significantly
decreased in the culture medium of choroid plexus epithelial cells
both 24 and 48 h after Aβ40 exposure compared to vehicle-treated
cell cultures (Figures 1B,C; p< 0.01). As expected, Aβ40 admin-
istration also induced an important reduction in expression of
membrane-bound megalin in cell lysates (Figure 1D).
EXTRACELLULAR MEGALIN IN HUMAN CSF
The fact that megalin is expressed by choroid plexus epithelial
cells, and is secreted into the extracellular medium, prompted
us to examine CSF for its presence. Statistical analysis for age
or gender revealed no significant differences between the four
diagnostic groups (AD, PD, and controls). Baseline biochemi-
cal characteristics of subjects included in this study were also
shown in Table 1. The mean MMSE (p< 0.05), tau (p< 0.01), and
Aβ42 (p< 0.05) CSF levels were significantly different between AD
group and control subjects (Table 1). Immunoblotting of human
CSF indeed revealed a single band (210 kDa) that cross-reacted
with mAb2E12 antibody, corresponding to megalin (Figure 2A).
Notably, in AD patients, soluble megalin levels in the CSF were
40% lower than in non-demented subjects and PD patients
(Figure 2A). Note that Aβ deposits were not detected in choroid
plexus from PD (1.07± 0.02 pg/ml) or non-demented subjects
(1.02± 0.05 pg/ml), whereas choroid plexus Aβ accumulations
were significantly increased in AD patients (3.77± 1.22 pg/ml,
p< 0.01 versus control group). These findings suggest that choroid
plexus Aβ accumulation might induce a decrease in CSF soluble
megalin, in accordance with previous in vitro data.
Whereas soluble LRP-1 normally circulates in plasma (Quinn
et al., 1997), in this study, we reported that soluble LRP-1 was also
detected in human CSF by Western blotting (Figure 2B). In AD
patients, soluble CSF LRP-1 levels were low but not significantly
lower than in non-demented controls (Figure 2B).
Because megalin binds Aβ (Hammad et al., 1997; Alvira-Botero
and Carro, 2010), and soluble LRP-1 also is a major binding pro-
tein for Aβ (Sagare et al., 2007), we hypothesized that soluble
megalin might also be involved in Aβ clearance in CSF. As shown
in Figure 3, in co-immunoprecipitation experiments, a substan-
tial amount of Aβ co-immunoprecipitated with both megalin
and LRP-1 from control CSF samples. In CSF samples from AD
patients, the amount of Aβ “pulled down” by megalin or LRP-1
was reduced (Figures 3A–C, upper panels). Although a similar
amount of Aβ was precipitated (Figure 3C, down panel), signifi-
cantly less megalin and LRP-1 were co-immunoprecipitated with
Aβ in CSF samples from AD patients (Figures 3A,C, upper pan-
els). This result was confirmed by a reversed immunoprecipitation
Frontiers in Cellular Neuroscience www.frontiersin.org April 2015 | Volume 9 | Article 134 | 3
Spuch et al. Soluble megalin in Alzheimer’s disease
FIGURE 1 | Immunolocalization of soluble megalin in cultured choroid
plexus. (A) The green fluorescence represents megalin signal in the culture
medium from choroid plexus epithelial cell cultures. The amount of megalin in
the culture media from these cells was markedly decreased following Aβ40
treatment for 24 and 48 h. (B) Culture media were resolved on SDS-PAGE,
and the amount of extracellular megalin after Aβ40 treatments was measured
on Western blots. (C) The histogram represents densitometric values from
three replicates. (D) A representative Western blot showing reduced
expression of membrane-bound megalin in cell lysates following Aβ40
treatment for 24 and 48 h. Results are expressed as mean±SEM. **p<0.01.
experiment, in which anti-megalin and LRP-1 antibodies were
used during precipitation, followed by detection of Aβ on Western
blots with anti-Aβ antibody (Figures 3B,D). The reduced amount
of Aβ co-immunoprecipitated with soluble forms of megalin and
LRP-1 was not due to a decrease in the amount of megalin and
LRP-1 precipitated by the antibodies, since similar amounts of
megalin and LRP-1 were detected from the precipitated samples
(Figures 3B,D, lower panels).
DISCUSSION
This study provides the first evidence for secreted soluble megalin
from rat choroid plexus epithelial cells. We also found that mega-
lin was present as a soluble receptor in CSF, possibly secreted by
choroid plexus epithelial cells, in agreement with previous studies
(Orlando and Farquhar, 1993; Kounnas et al., 1994).
Megalin is an endocytic membrane receptor of 600 kDa. It is
a transmembrane glycoprotein that has a relatively large extra-
cellular domain, a small cytoplasmic domain, and a single trans-
membrane domain that targets it to membrane domains rich in
cholesterol and glycosphingolipids (Marzolo et al., 2003), and is a
substrate for the γ-secretase complex (Zou et al., 2004; Biemesder-
fer, 2006). This last process involves proteolysis of the membrane
protein, culminating in the release of the intracellular domain of
megalin from the membrane (Zou et al., 2004). Previous studies
have indicated that megalin exists in two forms: a membrane-
bound form, and a soluble form (Bachinsky et al., 1993). Soluble
forms of megalin have been demonstrated to be released into the
medium of an immortalized rat proximal tubule cell line (Jung
et al., 1998), the supernatant of a yolk sac carcinoma cell line
(Orlando and Farquhar, 1993), into the endolymphatic sac (Ishida
et al., 2006), and into normal human urine (Kounnas et al., 1994;
Norden et al., 2002). In cultured epithelial cells of renal tubules
that express megalin, both “soluble” and “insoluble” forms of the
receptor have been reported (Bachinsky et al., 1993; Orlando and
Farquhar, 1993). It has been suggested that under some patholog-
ical conditions, a soluble form of megalin receptor is produced by
brain microvessels, choroid plexus, and/or ventricle ependyma and
transported to neuronal targets. All these findings are consistent
with a model of regulated processing of the receptor.
Soluble forms of megalin previously described (Bachinsky et al.,
1993; Orlando and Farquhar, 1993; Kounnas et al., 1994; Norden
et al., 2002; Ishida et al., 2006), and also showed in our study, are
fragments of approximately 200–220 kDa, suggesting that they are
truncated forms of the membrane-bound megalin. Some studies
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FIGURE 2 | Expression of megalin and LRP-1 in human CSF. (A) Soluble
megalin (A), and LRP (B) expression measured on Western blots in CSF
samples from non-demented subjects (controls; white), with Alzheimer’s
disease (AD; black), and Parkinson’s disease (PD; gray). Scatter plots
represent results from three replicates. Results are expressed as
mean±SEM. *p<0.05.
have shown that the ectodomain shedding of megalin is mediated
by a metalloprotease in an opossum kidney proximal tubule cell
line (May et al., 2002; Zou et al., 2004; Biemesderfer, 2006). Our
hypothesis supports previous studies reporting that several soluble
forms are produced by the release of the ectodomain via a single
proteolytic cleavage of the membrane receptors, whereas others
are secretory products.
Lipoprotein receptor-related protein 1, which also belongs to
the LDL gene family, is also subjected to regulated intramembrane
proteolysis (May et al., 2002). LRP-1 has been also reported to
be a substrate for both BACE and γ-secretase (Von Arnim et al.,
2005). BACE interacts with the intracellular domain of LRP-1,
induces LRP-1 extracellular domain cleavage, and the subsequent
release of the LRP-1 intracellular domain from the membrane.
BACE activity at endogenous levels leads to an increase in LRP-1
C-terminal fragment, and to the release of secreted LRP-1 in the
medium (Von Arnim et al., 2005). Since megalin is also a member
of this gene family and closely related to LRP-1, we suggested that
megalin could be proteolytically processed by similar mechanisms.
Indeed, BACE is present and active in choroid plexus (Crossgrove
et al., 2007; Dietrich et al., 2008).
The physiological significance of most soluble forms of the
receptor is poorly understood, although it is known that many
soluble forms have ligand-binding capacity. Preliminary data have
already identified soluble LRP-1 in plasma (Quinn et al., 1997).
Here, native soluble LRP-1 normally controls 70–90% of circu-
lating Aβ in humans through peripheral binding, regulating Aβ
metabolism and clearance under physiological conditions and in
AD. Soluble LRP-1 function is compromised in AD, which may
contribute to elevated brain Aβ (Sagare et al., 2007). In AD subjects,
there was an important drop in soluble LRP-1-bound Aβ associ-
ated with a severe increase in free, protein-unbound Aβ (Sagare
et al., 2007).
In a recent study with patients diagnosed with AD and diabetes
mellitus type-1, high levels of soluble LRP1 in CSF were described
compared with the control subjects (Ouwens et al., 2014). This
discrepancy with our data may be due to insulin levels, as it has
been reported that insulin promotes the synthesis of LRP-1 (Bell,
2012).
In the present study, we have detected both soluble megalin and
LRP-1 in CSF samples. Reduced soluble megalin after Aβ expo-
sure was not only detected in the choroid plexus culture medium
but also was found in the CSF from AD subjects compared to
non-demented controls, being absent in PD patients. We found
that Aβ40 treatment reduces soluble megalin levels in cultured
choroid plexus epithelial cells, suggesting that this extracellular
megalin isoform might be reduced under Aβ accumulation con-
ditions. This is in agreement with previous work showing that
soluble LRP function is compromised in AD, and may contribute
to elevated brain Aβ (Sagare et al., 2007). Taken into account that
Aβ peptides are accumulated in the choroid plexus in AD patients
(Dietrich et al., 2008), it might be suggested that Aβ initially causes
a reduction in soluble megalin levels.
Since megalin and LRP-1 have been also reported to be involved
in transport of Aβ from the CSF (Hammad et al., 1997), we next
showed that both megalin and LRP-1 were the main binding pro-
teins for Aβ in human CSF. After co-immunoprecipitation with
megalin and LRP-1-bound Aβ, we found that in AD patients there
is a reduction of binding affinity for Aβ with both soluble forms of
megalin and LRP-1 in CSF. There was a clear trend for megalin- or
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FIGURE 3 | Megalin-bound, and LRP-1-bound Aβ40 in human CSF.
(A–D) Co-immunoprecipitation of Aβ40 with megalin and LRP-1 in human CSF.
CSF samples were subjected to immunoprecipitation (IP) with an anti-Aβ
antibody (A,C), followed by detection of megalin, and LRP-1 on Western blots
(IB). Reversed immunoprecipitation with anti-megalin (B) and LRP-1
(D) antibodies followed by detection of Aβ with anti-Aβ antibody.
Densitometric values for co-immunoprecipitated Aβ with megalin and LRP-1
were normalized, respectively, against that for each precipitated receptor. The
histograms represent results from three replicates. Results are expressed as
mean±SEM. *p<0.05. AD, Alzheimer’s disease; PD, Parkinson’s disease.
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LRP-1-bound Aβ to decrease in AD patients compared to controls,
and PD patients.
It was described that in AD patients there is an oxidation of
LRP-1, resulting in a reduction of binding affinity for Aβ (Owen
et al., 2010). Although there is no evidence of similar megalin
oxidation, we cannot discount its possibility, which would result
in a reduction in Aβ clearance, and consequently, an increase in
brain Aβ.
The presence of megalin has been described in urine-derived
exosomes (Pisitkun et al., 2004; Fernandez-Llama et al., 2010).
Because exosomes are secreted from almost all cells, it is also pos-
sible that in other organs, as well as the kidney, the release of
exosomes containing megalin could be a physiological mechanism
to regulate the availability of ligands and/or to transport ligands
from one cell to another. Our present study did not discriminate
between megalin associated with exosomes and megalin derived
from protease-mediated shedding of the extracellular domain. It is
therefore possible that under some pathophysiological conditions,
the levels of megalin secreted in exosomes could be affected and
could serve a diagnostic biomarker. However, until now, there has
been no report indicating changes in the presence of megalin in
exosomes in different diseases, such as AD, and further research
will be required to understand this process.
In conclusion, in this study, we were able to identify soluble
forms of megalin and LRP-1 in human CSF. We also propose that
these soluble fragments could be used as biomarkers for AD diag-
nosis. Additionally, the complexes LRP1-Aβ and megalin-Aβ in
CSF could be regulating the availability, storage, and clearance
of Aβ from the brain to the blood. Thus, changes in the kinetic
affinity binding probably increase brain Aβ levels and consequent
Aβ-induced toxicity effects. It is possible that Aβ directly regulates
soluble megalin levels, and subsequently megalin-bound Aβ levels
in CSF are reduced in AD patients, which may contribute to ele-
vated brain Aβ. Finally, we also suggest that this effect might be
specific to AD and not to other neurodegenerative disorders, such
as PD. However, further studies using large cohorts are needed to
confirm this last hypothesis.
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